

THE CLAIMS

Please make the following amendments:

1. (cancelled)
2. (cancelled)
3. (cancelled)
4. (cancelled)
5. (cancelled)
6. (cancelled)
7. (previously presented) A composition useful for targeting tumor-derived endothelial cells, said composition comprising a peptide selected from the group consisting of SEQ ID NO 1 Cys-Gly-Gly-Arg-His-Ser-Gly-Gly-Cys; SEQ ID NO 2 Cys-Gly-Gly-Arg-Lys-Leu-Gly-Gly-Cys; SEQ ID NO 3 Cys-Gly-Gly-Arg-Arg-Leu-Gly-Gly-Cys; SEQ ID NO 4 Cys-Gly-Gly-Arg-Arg-Ser-Arg-Gly-Gly-Cys; and SEQ ID NO 5 Cys-Leu-Leu-Arg-Arg-Ser-Arg-Leu-Leu-Cys.
8. (previously presented) The composition of Claim 7, wherein said peptide is operatively attached to a therapeutic agent that is capable of exerting a cytotoxic effect on tumor vasculature.
9. (cancelled)
10. (previously presented) The composition of Claim 7, wherein said peptide is operatively attached to a therapeutic agent capable of exerting a cytotoxic effect on a tumor.
11. (previously presented) The composition of Claim 7, wherein the therapeutic agent includes at least one agent selected from the group consisting essentially of anticellular agents, chemotherapeutic agents, radioisotopes, and cytotoxins.

Serial No.: 09/810,700
Docket No.: 00-149-US

12. (original) The composition of Claim 11, wherein the therapeutic agent is an anticellular agent and said anticellular agent comprises a steroid, an antimetabolite, an anthracycline, a vinca alkaloid, an antibiotic, an alkylating agent, or an epipodophyllotoxin.

13. (original) The composition of Claim 11, wherein the therapeutic agent is an anticellular agent and said anticellular agent comprises a plant-, fungus- or bacteria-derived toxin.

14. (previously presented) The composition of Claim 11, wherein said therapeutic agent is a cytotoxin and said cytotoxin comprises an A chain toxin, a ribosome inactivating protein, gelonin, α -sarcin, aspergillin, restrictocin, a ribonuclease, diphtheria toxin, Pseudomonas exotoxin, a bacterial endotoxin, or the lipid A moiety of a bacterial endotoxin.

15. (original) The composition of Claim 7, formulated as a pharmaceutical composition.

16. (original) The composition of Claim 9, wherein the peptide attached to a therapeutic agent is capable of exerting a cytotoxic effect on tumor vasculature sufficient to lead to tumor necrosis.

17. (previously presented) The composition of Claim 7, wherein said peptide is linked to a diagnostic agent that is detectable upon imaging.

18. (original) The composition of Claim 17, wherein said diagnostic agent is selected from the group consisting of paramagnetic ions, radioactive ions and fluorogenic ions detectable upon imaging.

19. (original) The composition of Claim 18, wherein said diagnostic agent is a paramagnetic ion, and said paramagnetic ion is selected from the group consisting essentially of chromium (III), manganese (II), iron (III), iron (II), cobalt (II), nickel (II), copper (II), neodymium (III), samarium (III), ytterbium (III), gadolinium (III), vanadium (II), terbium (III), dysprosium (III), holmium (III) and erbium (III).

20. (original) The composition of Claim 18, wherein said diagnostic agent is a radioactive ion, and said radioactive ion is selected from the group consisting essentially of

Serial No.: 09/810,700
Docket No.: 00-149-US

iodine¹²³, technetium^{99m}, indium¹¹¹, rhenium¹⁸⁸, rhenium¹⁸⁶, copper⁶⁷, iodine¹³¹, yttrium⁹⁰,
iodine¹²⁵, astatine²¹¹, and gallium⁶⁷.

21. (cancelled)

22. (cancelled)

23. (cancelled)

24. (cancelled)